Modality development strategies

**Small Molecules**
- Kinase, PI, Receptor modulators; Molecular Glues, Bifunctional molecules, Small molecule targeting RNA for targeted protein degradation/upregulation
- **Targeted delivery**: prodrugs/polymer drug conjugates/targeted Lipid Nano Particles, Exosomes, Extracellular Vesicles
- Compound Library

**Oligonucleotides**
- Novel Monomers, Antisense Oligonucleotide (ASO) design technologies, ASO-conjugates, targeted saRNA, selective cell ligand targeting for neuronal cell delivery
- Oligo-Manufacturing

**Antibodies**
- Novel Formats: Ab Fragments, Single Domain Antibodies, Bi-/Multi-specifics, optimized Fc domains
- Novel technology platform for Antibody Hard-to-Drug targets
- Synthetic antibody libraries
- ADCs linkage Chemistry/Conditionally active antibody format

**AI driven Strategy**
- AI/ML Data-Driven Platform to support Target ID, Lead Generation & Drug Design Prediction methods for Antibody optimization
- AI/ML for drug repositioning, indication expansion, clinical combinations
Drug discovery and development technologies

**Phenotypic cell platforms and 3D models**
- iPSCs, patient derived models
- Co-culture models
- Organoids, tumoroids (PDAC, CRC, other solid tumors)
- Organ on a Chip (liver, brain, kidney)

**Protein Sciences**
- High throughput functional & stability antibody screening
- Antigen specific immuno-Oncology assays
- Microfluidic or micro array technology
- Multi-protein production
- High throughput Mass Spectrometry-based proteomic analysis approach
- Mass Spectrometry target

**Imaging**
- High content imaging (tissues/cells) and analysis
- Multimodal platforms – Multiplexing, Spatial multiOmics Strategy, Spatial Phenotypic quantification
- In vivo visualization of antisense oligonucleotides (ASO) biodistribution
- ASO tolerability assays

**Sample Optimization**
- Universal sample preparation
- Laser Capture Microdissection
- Single cell analysis ATAC (Assay for Transposase Accessible Chromatin)
- High throughpout Mass Spectrometry-based proteomic analysis approach

**Liquid Biopsies**
- Circulating tumor DNA (ctDNA) and Methylation assay development
- Exosomes or Extracellular Vesicle extraction from Blood for Biomarker identification
- Technology to improve sensitivity
- Computational methods for Next-Generation Sequencing

**Flow Chemistry**
- Multistep synthesis
- Photochemistry, Electrochemistry
- Automation of downstream process (quenching, phase separation, distillation)
- Continuous crystallisation/drying/milling
- In line analysis.
- Continuous manufacturing in Pharma
**Partnering with Servier**

Partnering is embedded in our culture with highly engaged and diverse teams partnering for a shared purpose - contributing to therapeutic progress to serve patient needs. Our partnership approach serves one goal: to bring life-changing treatments to patients faster. We strive to always put patients first, leading to better outcomes for ourselves and our partners.

**A partner of choice**

**A partner with strong commitment**

Servier is an independent pharmaceutical company committed to therapeutic progress to serve patient needs. Its unique governance allows Servier to reinvest all its profits to support its development, as well as plan and invest with a long-term view, in line with its vocation. Servier long-term vision applies to its partnership philosophy.

**A partner with a global presence**

With €4.9Bn of revenue in 2022 across 150 countries worldwide, the Group has a growing presence in the USA and Japan, a strong EU presence and a deep knowledge of emerging countries and China.

**A partner with proven expertise and experience**

Servier is very focused on specialty care oncology with a proven expertise of over 60 years in cardiovascular and metabolic diseases. It is developing new therapeutic solutions to serve unmet patient needs. From R&D to commercialization, we have proven experience to help new therapeutic innovations become reality for patients, alone or with partners.

**A partner you can rely on**

Servier is proud of what has been achieved with its partners so far. Servier has a strong track record of providing flexible partnership structures to its many partners, as well as an R&D infrastructure with 2,900 people in France, Hungary and Boston and an extensive commercial knowledge of global markets.

---

**Partnering interests**

### Oncology

**Discovery & Early Clinical Focus**

- Synthetic lethality
- Apoptosis
- Precision oncology
- Epigenetic regulators

**Late-stage Clinical Focus**

- Hematologic tumors (NHL, ALL, AML)

---

### Immuno-oncology

**Tumor micro-environment**

- T cell targeting

---

### Immuno-inflammation

**Modalities**

- Small molecules
- Antibodies, Bispecifics, ADCs

**Autoantibody-driven autoimmune diseases**

- And other diseases sharing similar pathophysiological mechanisms

---

### Neuroscience

**Modalities**

- Small molecules
- Oligonucleotides, ASO

**Hereditary forms of Parkinson Disease**

- Multiple System Atrophy
- Familial Amyotrophic Lateral Sclerosis
- Spinocerebellar Ataxia
- Progressive Supranuclear Palsy
- Genetically driven paediatric epilepsias

---

### Cardiovascular & Metabolism diseases

**Acquire or license market-ready or mature assets for some geographies**